Belite Bio FY2025 EPS Estimate Lowered by HC Wainwright

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Investment analysts at HC Wainwright lowered their FY2025 EPS estimates for Belite Bio in a note issued to investors on Monday, December 1st. HC Wainwright analyst Y. Chen now expects that the company will earn ($2.15) per share for the year, down from their prior forecast of ($1.97). HC Wainwright currently has a “Buy” rating and a $185.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q4 2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at $5.80 EPS and FY2026 earnings at $4.12 EPS.

Several other research firms have also recently commented on BLTE. Benchmark increased their price target on Belite Bio from $80.00 to $132.00 and gave the company a “buy” rating in a report on Friday, October 31st. Cantor Fitzgerald began coverage on Belite Bio in a research note on Monday, November 24th. They issued an “overweight” rating and a $154.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a report on Wednesday, October 8th. Wall Street Zen cut shares of Belite Bio from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Mizuho set a $194.00 price objective on shares of Belite Bio and gave the company an “outperform” rating in a report on Tuesday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Belite Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Belite Bio Price Performance

BLTE opened at $150.84 on Wednesday. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of -78.56 and a beta of -1.45. The company’s 50 day simple moving average is $100.24 and its two-hundred day simple moving average is $76.76. Belite Bio has a 1-year low of $49.00 and a 1-year high of $160.55.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings results on Monday, December 1st. The company reported $0.95 earnings per share for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BLTE. RA Capital Management L.P. acquired a new stake in shares of Belite Bio during the third quarter valued at about $64,750,000. Vestal Point Capital LP purchased a new position in shares of Belite Bio during the 3rd quarter worth approximately $23,125,000. Marshall Wace LLP increased its holdings in Belite Bio by 1,876.6% in the 3rd quarter. Marshall Wace LLP now owns 187,500 shares of the company’s stock valued at $13,875,000 after purchasing an additional 178,014 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Belite Bio in the first quarter valued at approximately $5,538,000. Finally, Millennium Management LLC purchased a new stake in Belite Bio in the third quarter valued at approximately $1,535,000. Hedge funds and other institutional investors own 0.53% of the company’s stock.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.